Has Karl Insogna received payments from drug or device companies?

Yes. Drug and device makers reported $67,944 in general payments to Karl Insogna across 46 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Karl Insogna did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Karl Insogna come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Karl Insogna

Endocrinology, Diabetes & Metabolism · New Haven, CTNPI 1346223559

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (53.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Kyowa Kirin, Inc. at 40.4% of the total. Reporting peaked in 2019 at $32,423 and has fallen 62.8% since, to $12,066 in 2025. Among endocrinology, diabetes & metabolism clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$67,944in general payments, 2019–2025

Across 46 payments — averaging $1477.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Kyowa Kirin, Inc.$27K
Ultragenyx Pharmaceutical Inc.$20K
Kyowa Kirin Co., Ltd$19K
Kyowa Kirin Services Ltd$2K
Amgen$14

$834,719in research payments, 2019–2025

Across 29 payments — averaging $28,783 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Ultragenyx Pharmaceutical Inc.$832K
Hologic Inc$3K

What the payments were for

Consulting fees$36,42854%
Travel & lodging$30,20744%
Food & beverage$1,2952%
Education$140%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Kyowa Kirin, Inc.	31	$27,444
Ultragenyx Pharmaceutical Inc.	7	$19,502
Kyowa Kirin Co., Ltd	5	$18,592
Kyowa Kirin Services Ltd	2	$2,393
Amgen	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

CRYSVITA$48,084

How this compares

$67,944 in reported general payments places this provider in the 90th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.

See all endocrinology, diabetes & metabolism providers in Connecticut →

Other endocrinology, diabetes & metabolism in New Haven

Ania JastreboffNew Haven$536K
Silvio InzucchiNew Haven$461K
Philip GoldbergNew Haven$324K
Kevan HeroldNew Haven$261K
Gerald ShulmanNew Haven$194K
Clemens BergwitzNew Haven$31K
Richard KibbeyNew Haven$18K
Peter TebbenNew Haven$17K
Surani FernandoNew Haven$13K
Irina RosewaterNew Haven$12K

See the full list for Connecticut →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →